Haematology 2018

RELEVANCE: OVERALL SURVIVAL (IMMATURE; ITT)

1.0

R-chemo

0.9

2

R

R-chemo (n= 517)

R 2

0.8

(n = 513)

0.7

Events, n (%)

38 (7)

31 (6)

0.6

94% (91%-96%) 94% (91%-96%)

0.5

3-year OS (95% CI)

0.4

1.16 (0.72-1.86)

HR (95% CI)

0.3

OS Probability

0.2

0.1

0.0

0 6 12 18 24 30 36 42 48 54 Months from Randomization

60 66

Number of Patients at Risk

513 499 491 486 479 459 312 194 105 24 0 2 R 2 517 496 487 481 470 453 298 193 115 32

R-chemo

0

Data cut-off31May2017. Fowleret al. RELEVANCE: Phase III Randomized Study of LenalidomidePlus Rituximab (R 2 ) Versus ChemotherapyPlus Rituximab,Followedby RituximabMaintenance,in PatientsWith Previously Untreated FollicularLymphoma. Oral presentation at:American Society of ClinicalOncology meeting.2018; Jun 1-5; Chicago,IL. Abstract 7500.